Creating nanoparticles to improve HIV-1 vaccine effectiveness
Project 2. cGMP manufacture of HIV-1 Env trimer sortase A-conjugated nanoparticles
This study is working on a new way to make tiny particles that show the HIV virus to the immune system in the right shape, which could help the body create stronger defenses and better antibodies against HIV, aiming to improve future vaccines for people at risk of the virus.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-11009923 on NIH RePORTER |
What this research studies
This research focuses on developing a new method to create nanoparticles that present HIV-1 envelope trimers in their correct form to the immune system. By using a technique called sortase A conjugation, the researchers aim to produce well-folded Env trimers that can enhance the immune response and induce broadly neutralizing antibodies. This approach seeks to overcome the challenges of misfolded proteins that can lead to ineffective immune responses. The goal is to create a rapid and efficient platform for HIV-1 vaccine design that could lead to better protection against the virus.
Who could benefit from this research
Good fit: Ideal candidates for this research would be individuals at high risk for HIV-1 infection or those interested in participating in HIV vaccine trials.
Not a fit: Patients who are already HIV-positive or those who do not meet the criteria for vaccine trials may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective HIV-1 vaccines that provide long-lasting protection against the virus.
How similar studies have performed: Other research has shown promise in using nanoparticle platforms for vaccine development, indicating that this approach could be a viable strategy.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Dickens, Jason — Duke University
- Study coordinator: Dickens, Jason
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.